Literature DB >> 1059494

Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.

F Cavalli, R Sonntag, K W Brunner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1059494      PMCID： PMC1674987          DOI： 10.1136/bmj.4.5990.227

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  1 in total

1.  Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults.

Authors:  J P Whitecar; G P Bodey; E J Freireich; K B McCredie; J S Hart
Journal:  Cancer Chemother Rep       Date:  1972-08
  1 in total
  4 in total

1.  Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.

Authors:  R Liang; E Chiu; T K Chan; D Todd
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Authors:  H J Schmoll; N Niederle; W Achterrath
Journal:  Klin Wochenschr       Date:  1981-11-02

4.  Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide.

Authors:  M Gore; R Powles; A Lakhani; S Milan; J Maitland; G Goss; A Nandi; T Perren; G Forgeson; J Treleaven
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.